Furthermore, mtm analogues have been shown to be effective against CLL cells, with EC-7072 inducing CLL cell death through targeting of BCR signalling [32], and administration of MTMOX32E to the Eμ-Tcl1 mouse model reduces the malignant cell burden [33]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.